Introduction 55
Stereotactic body radiation therapy (SBRT) is an innovative technique that delivers high-dose 56 radiation limited precisely to the region of the tumour [1, 2] . In SBRT for targets affected by 57 respiratory motion, such as lung tumours, appropriate motion management is recommended to 58 reduce doses delivered to the surrounding normal tissues. Several methods of accounting for 59 respiratory motion have been developed, including methods in which the radiation delivery is 60 synchronised with respiration; i.e. the dynamic tumour tracking (DTT) method and the 61 respiratory gating method [3] . 62
With the above respiratory-synchronised methods, markers implanted either in the 63 tumour itself or nearby are often used as the internal surrogate to localise the tumour position 64 [4] [5] [6] . However, the position of the implanted markers does not always represent the tumour 65 position because the tumour and markers move non-synchronously during respiration, 66 especially in cases in which the markers were located slightly distal from the tumour [7] . This 67 intrafractional positional difference between the tumour and markers should be incorporated 68 into the DTT or respiratory gating irradiation treatment plan by using a wider gating window, 69 within which the beam is delivered during the respiration cycle. Furthermore, the relative 70 position of the tumour with respect to the markers may vary from day to day; therefore, the 71 interfractional positional difference must be addressed. However, little about these variations 72 is known. 73
The purpose of this study was to quantify the intra-and interfractional variations 74 between the lung tumour position and the position of the implanted markers to evaluate the 75 margin necessary to account for the associated errors during respiratory-synchronised 76 irradiation treatment. 77
78

Patients and implanted markers 80
Fifteen patients who underwent SBRT for a solitary lung tumour were enrolled in this study. 81
With the approval of the Institutional Review Board, written informed consent was obtained 82 from all patients. One to two weeks prior to the date of the computed tomography (CT) 83 simulation, four or five disposable gold markers (Olympus Corporation, Tokyo, Japan), 84 spherical markers with a diameter of 1.5 mm, were implanted transbronchially. The insertion 85 technique was similar to the one reported by Harada et al [4] . Prior to the implantation, the 86 relative position between tumour and bronchi was evaluated on the multiplanar reformatted 87
CT images. The markers were implanted into the peripheral surrounding bronchi near tumour 88 under fluoroscopy guidance. A total of 66 markers were placed. The median interval between 89 marker placement and the CT simulation was 8 (range, 2 to 16) days. Twelve markers were 90 coughed up before CT simulation. After CT simulation, 2 markers were coughed up on the 91 seventh and thirteenth day, and 1 marker migrated on the sixth day after insertion. The 92 markers that coughed up or migrated after CT simulation during the treatment period were 93 excluded from this analysis. No adverse effect associated with the implantation was observed. 94
The characteristics of patients and tumours are shown in Table 1 . 95
96
Patient set-up and four-dimensional CT data acquisition 97
The patients were immobilised using vacuum immobilisation devices: BodyFix system 98 (Elekta AB, Stockholm, Sweden) or Esform (Engineering System, Nagano, Japan). After 99 set-up with skin marks, four-dimensional CT (4DCT) data were acquired using a 100 16-multidetector row CT: LightSpeed RT or BrightSpeed (General Electric Healthcare, 101
Waukesha, WI, USA) with an axial slice thickness of 2.5 mm. The cine duration time of the 102 scan at each couch position was set to 6.0 or 7.0 s, which was more than the maximum 103 The divergence in the range of intrafractional variations between patients is shown in Fig. 1,  155 and the values of E n in the respiratory phases (0≤n≤90) are shown in Fig. 2 . The means ± SD 156 of M n (0≤n≤90) were 0.1±0.1 mm, 0.3±0.2 mm, and 0.0±0.2 mm, and the RMS of SD n were 157 0.6 mm, 0.9 mm, and 1.5 mm in the RL, AP, and SI directions, respectively. These results 158
indicate that the systematic difference between respiratory phases is negligible. In addition, as 159 shown in Fig. 2 , the further towards inhale then the greater the intrafractional variations. 160
The tumour motion amplitude was positively correlated with the range of 161 intrafractional variations in all directions, and the tumour-marker distances were also 162 positively correlated in the AP and SI directions (Table 2) . 163
164
Interfractional variations 165
The median (range) interfractional variations were -0.1 mm (-2.4 to 0.7), 0.1 mm (-2.3 to 2.4), 166
and -0.6 mm (-1.3 to 1.6) in the RL, AP, and SI directions, respectively. As shown in Fig. 3 , 167 all interfractional variations were within 2.5 mm; the greatest variations were in the AP 168 may cause pneumothorax as a complication, which can delay radiation delivery and could be 177 life-threatening for those with comorbidities. The incidences of all pneumothorax and of those 178 to 67% and 16 to 40%, respectively [8] [9] [10] . By contrast, the reported incidence of 180 pneumothorax with the transbronchial approach is low [10-13] and in our series no 181 complication was observed. Therefore, the transbronchial approach is preferable due to its 182 less invasive nature. However, the placement of markers near or inside the tumour is more 183 difficult with the transbronchial approach than with the transcutaneous approach, because in 184 the former the markers are placed along the small bronchi near a tumour. The greater distance 185 between the tumour and markers leads to a larger positional error [14] . This error must be 186 considered when performing radiotherapy using markers placed outside the tumour. In the 187 current study, we quantified the intra-and interfractional positional variations between the 188 lung tumour and implanted markers using 4DCT scans to determine the necessary margin for 189 respiratory-synchronised irradiation using implanted markers. Another issue about the 190 markers implanted transbronchially is the low fixation rate. In our series, the fixation rate of 191 implanted markers was 77.3%: 51 of 66 markers implanted markers were fixed throughout 192 treatment. This is comparable to the reported fixation rate using the same insertion technique 193 [18]. The interfractional variations in the current study were evaluated using end-exhale phase 247 images under free breathing, which has high reproducibility compared with breath-holding. 248
Several limitations of our study should be mentioned. Firstly, the intrafractional 249 variations evaluated with 4DCT during a few respiration cycles may not be representative of 250 those during treatment in some patients although a single 4DCT is thought to be reliable for 251 the tumour motion in the majority of patients [19] . Therefore, in our institution, we validate 252 Fig. 1 . 
